Frontiers in Pharmacology
Multiple myeloma (MM) is a plasma cells neoplasm. The overexpression of Bcl-2 family proteins, particularly myeloid cell leukemia 1 (Mcl-1), plays a critical role in the pathogenesis of MM. The overexpression of Mcl-1 is associated with drug resistance and overall poor prognosis of MM. Thus, inhibition of the Mcl-1 protein considered as a therapeutic strategy to kill the myeloma cells. Over the last decade, the development of selective Mcl-1 inhibitors has seen remarkable advancement. This review presents the critical role of Mcl-1 in the progression of MM, the most prominent BH3 mimetic and semi-BH3 mimetic that selectively inhibit Mcl-1, and could be used as single agent or combined with existing therapies.
Al-Odat, O., von Suskil, M., Chitren, R., Elbezanti, W., Srivastava, S., Budak-Alpddogan, T., Jonnalagadda, S., Aggarwal, B., & Pandey, M. (2021). Mcl-1 Inhibition: Managing Malignancy in Multiple Myeloma. Frontiers in pharmacology, 12, 699629. https://doi.org/10.3389/fphar.2021.699629
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
This article has been corrected. See Front Pharmacol. 2021 August 31; 12: 758130.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.